Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
Carillon Tower Advisers, an investment management company, released its 'Carillon Eagle Small Cap Growth Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund's top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company. The one-month return of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was 2.86%, and its shares gained 50.15% of their value over the last 52 weeks. On May 23, 2025, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stock closed at $45.66 per share with a market capitalization of $2.83 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in its Q1 2025 investor letter:
"Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a leading biotechnology company focused on developing drugs for rare and preventable diseases. The company has two key assets: rusfertide for the treatment of polycythemia vera (a type of blood cancer) and icotrokinra for the treatment of psoriasis and ulcerative colitis. During the first quarter, a major pharmaceutical company announced that icotrokinra met its primary endpoint in a phase 2 trial in patients with ulcerative colitis, achieving a clinical remission rate that is among the highest for oral therapies addressing this condition. This positive outcome contributed to the strong performance in the stock."
A research scientist wearing a lab coat working with precision in a biopharmaceutical laboratory.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Protagonist Therapeutics, Inc. (NASDAQ:PTGX) at the end of the first quarter, which was 37 in the previous quarter. While we acknowledge the potential of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and shared the list of best cancer stocks to invest in for long term gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Everything you need to know about headaches for Headache Awareness Month
NEW HAVEN, Conn. (WTNH) — June is Headache Awareness Month. In today's health headlines, we discuss what to know about the most common headache types, how to tell them apart, and tips for preventing a tension headache. Dr. Vanessa Cooper, Yale Medicine neurologist specializing in headaches and assistant professor at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss. Watch the video above to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
13 minutes ago
- Yahoo
UAE's data center project with U.S. tech firms faces security concerns
-- A massive deal to create one of the world's largest data center hubs in the United Arab Emirates (UAE) with American technology, continues to face persistent security concerns, according to a Friday report by Reuters. The deal, worth billions of dollars, is reportedly far from finalized. The proposed site, spanning 10 square miles, is financed by G42, a tech company linked to the Emirati state. G42 is spearheading the development of the UAE's artificial intelligence (AI) industry. Tech giants Nvidia (NASDAQ:NVDA), OpenAI, Cisco (NASDAQ:CSCO), Oracle (NYSE:ORCL), and Japan's SoftBank (TYO:9984) are collaborating with G42 on the initial phase of the project, dubbed Stargate UAE, which is slated to launch in 2026. However, U.S. officials are yet to establish the security conditions for exporting the advanced chips or how the agreement with the Gulf state will be enforced. This leaves the deal unresolved. During a visit by then-President Trump, Abu Dhabi pledged to align its national security regulations with Washington's, including measures to prevent the misuse of U.S. technology. Concerns remain about the UAE's close ties with China, with the report noting that these issues have been consistent during both Biden and Trump administrations. The primary concern is the reliability of the Gulf state as a strategic partner. The report didn't indicate if new evidence had surfaced, but stated that existing concerns are still not addressed. During Trump's first term, the UAE and other Gulf states proceeded with the deployment of Huawei 5G technology, despite opposition from the U.S. Some U.S. officials also question whether the UAE can effectively prevent American technology from reaching Washington's adversaries, the report added. Related articles UAE's data center project with U.S. tech firms faces security concerns Melius upgrades Deere on long-term tech moat and recurring revenue upside Taseko Mines shares surge on landmark agreement with Tŝilhqot'in Nation
Yahoo
14 minutes ago
- Yahoo
Energy and tech stocks help lift S&P/TSX composite, U.S. stocks also higher
TORONTO — Canada's main stock index was up in late-morning trading, helped by strength in energy and technology sectors, while U.S. stock markets also climbed higher. The S&P/TSX composite index was up 81.84 points at 26,424.13. In New York, the Dow Jones industrial average was up 353.70 points at 42,673.44. The S&P 500 index was up 53.32 points at 5,992.62, while the Nasdaq composite was up 198.88 points at 19,497.33. The Canadian dollar traded for 73.04 cents US compared with 73.21 cents US on Thursday. The July crude oil contract was up US$1.10 at US$64.47 per barrel and the July natural gas contract was up two cents US at US$3.70 per mmBTU. The August gold contract was down US$23.10 at US$3,352.00 an ounce and the July copper contract was down five cents US at US$4.88 a pound. This report by The Canadian Press was first published June 6, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
